Cancer comprises a bewildering assortment of diseases that kill 7.5 million people each year. Poor understanding of cancer's diversity currently thwarts our goal of a cure for every patient, but recent integration of genomic and stem cell technologies promises a route through this impasse.
Lessons from Leukemia Different types of chromosomal translocations-the principal oncogenic mutations in the blood-have long been associated with specific subtypes of leukemia. Genomic, stem cell, and cancer assays have taught us important lessons about the basis of this ''matching.'' First, the different forms of leukemia appear to arise from distinct points in the hematopoietic lineage that are susceptible to specific translocations. For example, the BCR-ABL translocation seen in human chronic myeloid leukemia (CML) only initiates CML in uncommitted hematopoietic stem cells (HSCs) (Huntly et al., 2004) , whereas translocations involving the mixed-lineage leukemia (MLL) gene can initiate acute leukemias in both HSCs and committed progenitor cells (Barabé et al., 2007; Chen et al., 2008; Krivtsov et al., 2006) .
What is the biology behind this translocation-lineage stage matching? Comparative gene expression profiling suggests that the answer might lie in the capacity of translocations to activate key leukemogenic programs. Extensive self-renewal is considered a requisite feature of leukemic stem cells. When committed, nonself-renewing granulocyte macrophage progenitors (GMP) are transduced with MLL-AF9, they generate AML. The leukemic stem cells in this model retain a GMP-like gene expression profile, but they also acquire an aberrant self-renewal signature and self-renewal capacity, normally seen only in HSCs (Krivtsov et al., 2006) . Because BCR-ABL does not appear to activate self-renewal, but rather enhanced cell proliferation and survival, its leukemogenic potential might be restricted to HSCs that already possess the capacity to self-renew (Huntly et al., 2004; Schemionek et al., 2010) . Further probing of gene expression profile differences between normal and transformed hematopoietic cells has also highlighted new therapeutic opportunities. The transcriptome of MLL-AF9 transformed GMPs encodes a reactivated b-catenin (Ctnnb1) signal that drives leukemogenic self-renewal and that might be blocked for therapeutic gain (Wang et al., 2010) .
Although it is intuitive that cancers arise from specific combinations of mutations and susceptible cell types, these landmark studies of leukemia demonstrate the power of genomic technologies to decipher this process. Importantly, these data demonstrate that mutations can activate oncogenic signals without globally reprogramming the initiating cell. As we shall see, the legacy of the initiating cell transcriptome within cancer cells can provide crucial clues to tumor origins as well as unmask novel therapeutic targets.
Charting Cancer Origins in Solid Tissues
The availability of assays for each stage in the hematopoietic lineage, as well as the liquidity of blood, has accelerated understanding of leukemogenesis beyond that of solid tumorigenesis. But studies of solid cancers are catching up. The rigid anatomical organization of solid tissues has allowed investigators to map cells that express transcriptomes similar to those seen in cancers, and improved techniques to isolate and culture cells in solid tissue hierarchies have advanced the study of these populations. These studies have identified cells in solid tissues that share the transcriptomes of solid tumors and might therefore initiate cancer (Figure 1) .
Like most solid tissues, those of the central nervous system (CNS) give rise to a variety of cancers classified according to patterns of histology. Intracranial ependymomas are the third most common brain tumor of children and carry a much worse prognosis than spinal forms of the disease that predominate in adults. Ependymomas contain transcriptomes and DNA copy number alterations that correlate with tumor location (Johnson et al., 2010; Taylor et al., 2005) . Similarly, gene expression profiles of medulloblastomas-the most common malignant pediatric brain tumor-carve these cancers into clinically and molecularly distinct subgroups, including the Sonic Hedgehog (SHH) subtype driven by aberrant SHH signaling and the highly curable WNT subtype containing mutations in CTNNB1 (Northcott et al., 2010) .
To uncover the cellular origins of these diverse brain tumors, investigators tested the hypothesis that brain tumor subtypes inherit significant portions of their transcriptome from initiating CNS cells. Initial in situ hybridization analyses showed that the subventricular zone of the embryonic lateral ventricle and peri-canal region of the adult spine express the transcriptomes of human cerebral and spinal ependymoma, respectively (Taylor et al., 2005) . Because these regions house neural stem cells (NSCs), the investigators looked for transcriptomic similarities between regionally and developmentally discrete mouse NSCs and human ependymomas (Johnson et al., 2010) . Using a powerful new cross-species genomics algorithm, the investigators pinpointed embryonic cerebral and adult spinal NSCs as candidate cells of origin of cerebral and spinal ependymomas, respectively. This approach has also provided clues to the origins of medulloblastomas, yielding the surprising insight that some of these tumors might arise outside of the cerebellum (Gibson et al., 2010) . SHH subtype medulloblastomas have been shown to arise from committed cerebellar granule neuron precursor cells (GNPCs) Yang et al., 2008) . Not surprisingly, therefore, in situ hybridization and cross-species genomics revealed a close match between SHH subtype medulloblastomas and GNPC transcriptomes (Gibson et al., 2010) . In stark contrast, the transcriptome of WNT subtype medulloblastoma matched that of neural precursor cells of the lower rhombic lip and embryonic dorsal brainstem (Gibson et al., 2010) . Remarkably, magnetic resonance imaging demonstrated that, whereas human SHH subtype medulloblastomas are confined to the cerebellum, WNT subtype tumors invariably involve the dorsal brainstem, supporting further the notion that these different tumor types have distinct cellular origins (Gibson et al., 2010) .
Clues to cancer origins are not just present in the transcriptomes of leukemias and brain tumors, but have also been uncovered through comparative profiling of breast cancers and the normal mammary gland. The ducts and lobules of the human breast are lined by two cell layers: an inner luminal cell population and a heterogeneous outer cell layer that includes basal progenitor cells. Basal-like breast cancers, so called for their basal cell immunophenotype (cytokeratins 5/6, 14, and 17), are aggressive tumors, particularly prevalent among women with germline mutations in BRCA1. It seemed intuitive that basal-like tumors would arise from basal progenitor cells; however, recent data suggest these cancers actually arise from luminal progenitors. The preneoplastic breasts of BRCA1 mutant woman contain an expanded population of aberrant luminal progenitor cells, and the transcriptomes of BRCA1 mutant breast tissue and basal-type breast cancers are more like that of luminal progenitors than other normal breast cell types (Lim et al., 2009 . In contrast, the mammary glands of MMTV-neu mice contain normal numbers of MaSCs and develop luminal breast cancers, whereas forced expression of Notch1 in MaSCs expands the luminal progenitor population, leading to basallike breast cancers (Bouras et al., 2008) . Targeting tumor type-specific mutations to transcriptomematched normal cells has provided direct evidence that comparative gene expression profiling can identify cancer origins (Figure 2 ). In the breast, conditional deletion of Brca1 from mouse luminal progenitors, but not basal progenitors, produced tumors that mimic the histology and transcriptome of human BRCA1 mutant and sporadic basal-type breast cancers, thus confirming comparative gene expression profile predictions (Lim et al., 2009; Molyneux et al., 2010) . Similarly, embryonic cerebral NSCs that were predicted by transcriptome mapping to initiate cerebral ependymomas generated these tumors when challenged with mutations found exclusively in this form of the human disease (Johnson et al., 2010) . Further, mouse models have validated the surprising prediction that WNT subtype medulloblastomas likely arise from progenitor cells in the dorsal brainstem (Gibson et al., 2010) . Mutation of Ctnnb1-an invariable feature of WNT subtype medulloblastoma-had little impact on progenitor cell populations in the cerebellum but caused the abnormal accumulation of neuron precursor cells in the dorsal brainstem that progressed to form medulloblastomas that recapitulate the anatomy and gene expression profiles of human WNT subtype medulloblastoma.
Further study will doubtless reveal significant exceptions and nuances in the relationship between the transcriptomes of normal cells and their malignant offspring. Nevertheless, integrated genomic and stem cell studies have provided a useful framework for investigating the origin of cancer subtypes.
In the Right Place at the Wrong Time Tissues have been viewed largely as passive players in cancer pathogenesis-their risk of malignant transformation being dictated by heritable mutations and environmental exposures. But if cancers arise from preordained combinations of specific cell types and matched mutations, then the availability of either of these factors could dictate the epidemiology of cancer. In its broadest terms, this concept is not new. The very different cancer types observed in children and adults have long been suspected to have their roots in development (Figure 1) . Figure 1 can be modeled accurately when transcriptome-matched normal cell types are challenged with mutations found in the corresponding cancer. These models should prove extremely useful for developing new therapies for specific cancer subgroups.
However, evidence is emerging that more subtle shifts in the makeup of cell hierarchies might account for changes in cancer incidence. For example, it is tempting to speculate that the expanded population of aberrant luminal progenitors seen in the breasts of cancer-free patients carrying the BRCA1 mutation provides a source of cells that are susceptible to additional transforming mutations and thereby an increased risk of developing basal-type cancers (Lim et al., 2009; Molyneux et al., 2010) .
Shifts in cell hierarchies might also explain the association between certain physiological states and cancer. For example, if the massive progesterone-induced increases in mouse MaSCs prove to occur in humans, then this may explain why breast cancer is associated with early menarche, late menopause, and the inclusion of progestin in hormone replacement therapy (Joshi et al., 2010) .
As genomic and stem cell technologies allow further dissection of cancer subgroups and their origins, it will be interesting to see whether these studies provide answers to other key questions about cancer epidemiology. For example, do temporal changes in the GNPC lineage explain why SHH subtype medulloblastoma incidence peaks in both early childhood and later life (Northcott et al., 2010) ? And might the close matching of adult spinal NSC and spinal ependymoma transcriptomes explain why these tumors occur almost exclusively in adults (Johnson et al., 2010) ?
Toward Cancer Cures
Most biomedical discoveries rarely translate rapidly into improved patient care. However, recent discoveries that genomic tools can identify robust cancer subgroups, and point to the origins of these cancers, have immediate clinical relevance. This promise lies in the profound implications that this information holds for the full spectrum of cancer research.
Nonspecific cytotoxic treatments remain the mainstay of cancer therapy. Efforts to introduce more directed treatments that target mutant proteins in cancers have met with mixed results. The inefficiency of this process results, in part, from prior failures to adequately capture the heterogeneity of cancers in preclinical models. The integration of stem cell biology and genomics outlined in this Minireview is producing multiple, highly accurate models of human cancer subgroups (Gibson et al., 2010; Johnson et al., 2010; Molyneux et al., 2010; Yang et al., 2008) . Preclinical drug development using these models should allow investigators to better predict which forms of leukemias and solid cancers are most likely to respond to certain treatments (Figure 2 ). Such preclinical data could then be used to design genomic metrics that would direct treatments to the most appropriate patients in early clinical trials.
Cancer models built from specific cells of origin offer an additional advantage to drug developers. Therapies that cripple critical processes in cancer cells carry significant risks of damaging normal cell hierarchies. Understanding the origin of cancers might therefore allow the development of effective drugs with fewer side effects. For example, evidence that Ctnnb1-mediated self-renewal driven by MLL-AF9 in AML is not required by adult HSCs suggests that CTNNB1 might be targeted therapeutically in this disease without incurring significant hematological toxicity (Wang et al., 2010) .
Finally, the approaches outlined here promise to shed light on one of the greatest contemporary controversies in cancer research: the cancer stem cell hypothesis. Evidence that cancers are propagated and maintained by subpopulations of stem-like cancer cells has come largely from studies of human cancer xenografts in mice. But these systems do not allow lineage tracing of cancer development, and their interpretation is complicated by species differences. New mouse models of human tumors initiated from predefined and selected cells are enabling investigators to track tumorigenesis with much greater precision. Comparative genomic studies of initiating and daughter cancer cells should provide a more comprehensive view of the processes that cause and propagate cancer.
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